Printer Friendly

Framingham study data: ca diagnosis linked to rise in CV risk.

SAN FRANCISCO -- A diagnosis of cancer more than doubles the risk that a patient with known atherosclerosis will develop coronary heart disease or a cerebrovascular accident within 6 months, Dr. Bernard E. Kreger said in a poster presented at a conference on cardiovascular disease epidemiology and prevention sponsored by the American Heart Association.

People without atherosclerosis have no increase in cardiovascular risk after a cancer diagnosis, said Dr. Kreger of Boston University. The data come from the first two generations of the Framingham Heart Study, involving 5,514 women and 4,819 men.

Through 1999, 1,988 men experienced 4,431 circulatory events, and 1,614 women experienced 3,201 circulatory events. During the course of the study, 3,062 malignancies were detected among 2,577 cohort members. After adjustment for traditional risk factors for cardiovascular disease, members of the cohort had about a 2.4-fold increase in the risk of new coronary heart disease or cerebrovascular accident within the 6 months after a cancer diagnosis. At 1 year and 5 years after the cancer diagnosis, on the other hand, the investigators found no increase in risk.

Dr. Kreger speculated that the increase in risk might stem from something related to cancer itself or from psychological factors. Tumors might produce a substance that increases blood clotting.

Alternatively, the shock of a cancer diagnosis might trigger cardiovascular or cerebrovascular events.

Dr. Kreger suggested that no matter what the cause of the increased risk, physicians and family members should be watchful and careful when revealing a cancer diagnosis to a patient, especially one known to have circulatory disease.
COPYRIGHT 2004 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Clinical Rounds
Author:Finn, Robert
Publication:OB GYN News
Date:Jun 15, 2004
Words:266
Previous Article:Direct-to-consumer marketing: excessive public enthusiasm for ca screening.
Next Article:More common in pregnancy: don't overlook restless legs syndrome diagnosis.
Topics:


Related Articles
Framingham score getting scrutinized.
Framingham data show cancer dx increases cardiovascular risk.
Cancer Dx increases risk of cardiovascular event.
CA 125 testing not helpful after ovarian cancer: study found no advantage at follow-up.
Influence of imprecision on ROC curve analysis forc cardiac markers.
Biological variation of tumor markers and its application in the detection of disease progression in patients with non-small cell lung cancer.
Near-bedside whole-blood cardiac troponin I assay for risk assessment of patients with acute coronary syndromes.
Laboratory-based calculation of coronary heart disease risk.
Evaluation of the analytical and clinical performance of the Elecsys[R] CA 15-3 immunoassay.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters